TF and COVID-19: Together with the occurrence of TF-positive platelets (178) and augmented circulating PMVs (46), these findings provide evidence of the pro-thrombotic and pro-coagulatory microenvironment in COVID-19, which results in thrombotic complications in lungs and other tissues (170).